BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


NovaBay Pharmaceuticals, Inc. 

5980 Horton Street
Suite 550
Emeryville  California  94608  U.S.A.
Phone: 510-899-8800 Fax: 510-779-5468


View Clinical Trials from BioPharm Insight

NovaBay Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with its two distinct categories of products: Aganocide® compounds and NeutroPhase®. Aganocide compounds, led by NVC-422, are patented, synthetic molecules with a broad spectrum of activity against bacteria, viruses and fungi. Mimicking the mechanism of action that human white blood cells use against infections, Aganocides possess a very low likelihood that bacteria or viruses will be able to develop resistance, which is critical for advanced anti-infectives. Having demonstrated clinical efficacy in Phase 2 proof-of-concept clinical studies, NVC-422 is suited to treat and prevent a wide range of local, non-systemic infections. NovaBay’s clinical development activities are focused on three disease areas: Dermatology, Ophthalmology and Urology.

NovaBay has entered into a licensing and research collaboration agreement with Galderma S.A., a global leading pharmaceutical company dedicated exclusively to the field of dermatology. NovaBay is also developing NeutroPhase, which is an FDA 510(k)-cleared product for advanced wound care. NovaBay believes that NeutroPhase is the only patented pure hypochlorous acid solution available which has the potential to be best suited to treat the six-million-patients in the U.S. who suffer from chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers.

 Key Statistics

Ownership: Public

Web Site: NovaBay Pharmaceuticals, Inc.
Symbol: NBY

 Company News
NovaBay Pharmaceuticals, Inc. (NBY) Reports 2015 First Quarter Financial Results And Provides Business Update 5/14/2015 12:30:50 PM
NovaBay Pharmaceuticals, Inc. (NBY) To Feature Key Opinion Leaders In Ophthalmology And Optometry At Analyst And Investor Day Event On May 19 5/11/2015 11:52:05 AM
NovaBay Pharmaceuticals, Inc. (NBY)’ Avenova Brings Significant Improvement To Patients With Blepharitis, New Study Finds 5/7/2015 1:26:16 PM
New Laboratory Study Shows That NovaBay Pharmaceuticals, Inc. (NBY)’ Avenovacompletely Inactivates The Bacterial Enzyme That Contributes To Blepharitis And Meibomian Gland Dysfunction 5/7/2015 11:08:42 AM
NovaBay Pharmaceuticals, Inc. (NBY) Signs Distribution Agreement With AmerisourceBergen Corporation (ABC) For Avenova 4/16/2015 10:57:43 AM
NovaBay Pharmaceuticals, Inc. (NBY) Appoints Mark M. Sieczkarek Chairman 4/14/2015 11:10:35 AM
NovaBay Pharmaceuticals, Inc. (NBY) Reports 2014 Fourth Quarter And Full Year Financial Results And Provides Business Update 3/26/2015 12:52:31 PM
NovaBay Pharmaceuticals, Inc. (NBY)’s Avenova Featured In Ophthalmology Management 3/24/2015 10:57:46 AM
The National Necrotizing Fasciitis Foundation Names NovaBay Pharmaceuticals, Inc. (NBY)'s Neutrophase As Its Official "Flesh Eating Disease" Wound Cleanser 3/17/2015 10:54:59 AM
NovaBay Pharmaceuticals, Inc. (NBY) Provides Update On Avenova Sales Growth 3/16/2015 12:56:31 PM